Key result
Newly detected AF after stroke linked to ~77% higher 3-month mortality vs previously known AF.
Why the study?
Newly detected atrial fibrillation after stroke has a different pathophysiology than previously known atrial fibrillation, but differences in clinical characteristics and outcomes between them have not been well studied.
Does newly detected atrial fibrillation after stroke (AFDAS) worsen mortality and functional outcomes compared to previously known atrial fibrillation (KAF) in acute ischemic stroke patients?
Cohort (n=698)
No
Does newly detected atrial fibrillation after stroke (AFDAS) worsen mortality and functional outcomes compared to previously known atrial fibrillation (KAF) in acute ischemic stroke patients?
Odds Ratio: 1.77 (95% CI 1.07–2.92)
Absolute Event Rate: 15.2% vs 10.3%
p-value: p=0.03
Newly detected atrial fibrillation after stroke is associated with a higher risk of 3-month mortality and worse functional outcomes compared to previously known AF, potentially driven by lower utilization of in-hospital anticoagulation.
AFDAS signals higher short-term mortality than KAF after stroke; leaves open whether targeted anticoagulation improves outcomes.
BACKGROUND: Newly detected atrial fibrillation after stroke (AFDAS) is a specific type of AF and have a different pathophysiology compared to patients with previously known AF before a stroke (KAF). However, the characteristics and outcomes between AFDAS and KAF have not been well studied. We aimed to further explore the clinical characteristics and long-term functional outcomes between AFDAS and KAF. MATERIALS AND METHODS: We retrospectively analyzed acute ischemic stroke patients admitted to our hospital between 2010 and 2017, who was also diagnosed with AF. The poor outcome was defined by the combination of death and any disability as scored by the modified Rankin Scale (mRS) score at 3 months and 12 months. RESULTS: Among the final sample of 698 patients, 370 (53%) were classified into KAF and 328 (47%) were AFDAS. Compared to KAF, patients with AFDAS had a lower prevalence of hypertension (P = 0.01), previous stroke (P = 0.02), higher prevalence of valvular heart disease (P = 0.02), less prescribed with anticoagulants during the hospitalization (P < 0.01), and higher mortality at 3 months (OR 1.77, 95%CI 1.07-2.92, P = 0.03). Patients with AFDAS had an increased trend of mRS score compared to KAF (3 months, OR 1.37, 95% CI 1.04-1.81, P = 0.02; 12 months, OR 1.32, 95%CI 1.01-1.75, P = 0.04). CONCLUSION: Patients with AFDAS had a higher risk of death and an increased trend of mRS score compared to KAF. Lower utilization of anticoagulation may be a major reason of worse outcome in AFDAS. Further investigation is required to identify whether the differences of the outcomes between AFDAS and KAF is confounded by pre-existing anticoagulation.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) conducted a cohort in Acute ischemic stroke with atrial fibrillation (n=698). Newly detected atrial fibrillation after stroke (AFDAS) vs. Previously known atrial fibrillation before stroke (KAF) was evaluated on Mortality at 3 months (OR 1.77, 95% CI 1.07-2.92, p=0.03). Newly detected atrial fibrillation after ischemic stroke was associated with a significantly higher risk of mortality at 3 months (adjusted OR 1.77) compared to previously known atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: